Escleroterapia local con Polidocanol (Etoxisclerol®) para el tratamiento de las epístaxis en la enfermedad de Rendu-Osler-Weber o Telangiectasia Hemorrágica Hereditaria (HHT)
[EN] Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber disease is a rare multisystemic vascular disease with an autosomal dominant inheritance pattern. The mutations lead to vascular malformations in different locations, such as telangiectases in the nasal and gastric mucosa and arterioven...
| Autor: | |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2014 |
| País: | España |
| Institución: | Universidad de Salamanca (USAL) |
| Repositorio: | GREDOS. Repositorio Institucional de la Universidad de Salamanca |
| OAI Identifier: | oai:gredos.usal.es:10366/125013 |
| Acceso en línea: | http://hdl.handle.net/10366/125013 |
| Access Level: | acceso abierto |
| Palabra clave: | Otorrinolaringología Telangiectasia Hemorragica Hereditaria Enfermedad de Rendu-Osler-Weber Epístaxis Polidocanol Inyección submucosa Hereditary Haemorrhagic Telangiectasia Rendu-Osler-Weber Epistaxis Polydocanol Submucosal injection 32 Ciencias médicas |
| Sumario: | [EN] Hereditary Haemorrhagic Telangiectasia or Rendu-Osler-Weber disease is a rare multisystemic vascular disease with an autosomal dominant inheritance pattern. The mutations lead to vascular malformations in different locations, such as telangiectases in the nasal and gastric mucosa and arteriovenous malformations in liver, lungs and brain. Epistaxis or nose bleeding results from ruptures of telangiectases present in the nasal mucosa, and it is the most frequent clinical manifestation appearing in 93% of HHT patients and leading many patients to have a poor quality of life. Several treatments have been used to reduce epistaxis, but none have been completely effective: from nose packing, to selective and supraselective embolizations, including pharmacological therapy, chemical cauterizations, laser or more aggressive surgical techniques, such as septodermoplasty or Young’s occlusion. Sclerotherapy in the treatment of epistaxis in HHT, using different compounds Ethybloc®, Fibrin glue (Tissucol®), Polydocanol (Aethoxysclerol®) have also been used. We were the first to use the Polydocanol or Lauromacrogol 400 (Aethoxysklerol®) in nasal submucosal infiltrations in all the world and our first results were published in 2000. So far, we have treated 105 patients since 1996, all under local anesthesia, and the results have been highly satisfactory with up to 95% improvement in effectively controlling epistaxis, as well as a high level of patient satisfaction, and with 2.0 % showing minimal side effects. |
|---|